Recombinant Mouse Pcsk9, His-tagged, C13&N15 Labeled

• Cat.No.: Pcsk9-197M
• Product Overview: Recombinant Mouse PCSK9 MS Standard Protein, C13 and N15-labeled (Mouse PCSK9, Heavy Labeled) Gln 35 - Gln 694 (Accession # AAH38085.1) was produced in human 293 cells (HEK293) with fully chemically defined cell culture medium to obtain >99% incorporation

Specification

• Description: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is also known as NARC1 (neural apoptosis regulated convertase), is a newly identified subtilase belonging to the peptidase S8 subfamily. Mouse PCSK9 is synthesized as a soluble zymogen, and undergoes autocatalytic intramolecular processing in the endoplasmic reticulum, resulting in the cleavage of its propeptide that remains associated with the secreted active enzyme with a broad alkaline pH optimum. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
• Source: HEK293
• Species: Mouse
• Tag: His
• Predicted N Terminal: Gln 35
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
• Molecular Mass: Mouse PCSK9, Heavy Labeled is fused with polyhistidine tag at the C-terminus, and has a calculated MW of 72 kDa. The predicted N-terminus is Gln 35. DTT-reduced Protein migrates as 20 kDa and 64 kDa in SDS-PAGE due to glycosylation and proteolytic digesti
• Endotoxin: Less than 1.0 EU per μg of the Mouse PCSK9, Heavy Labeled by the LAL method.
• Purity: >97% as determined by SDS-PAGE.
• Applications: MS Standard Protein
• Storage: Avoid repeated freeze-thaw cycles.No activity loss was observed after storage at:In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).

Gene Information

• Gene Name: Pcsk9 proprotein convertase subtilisin/kexin type 9 [ Mus musculus ]
• Official Symbol: Pcsk9
• Synonyms: PCSK9; proprotein convertase subtilisin/kexin type 9; NARC-1; convertase subtilisin; proprotein convertase 9; proprotein convertase PC9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; neural apoptosis-regulated convertase 1; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; MGC47409
• Gene ID: 100102
• mRNA Refseq: NM_153565
• Protein Refseq: NP_705793
• Pathway: NGF processing, organism-specific biosystem; Signal Transduction, organism-specific biosystem; Signalling by NGF, organism-specific biosystem
• Function: apolipoprotein receptor binding; hydrolase activity; identical protein binding; low-density lipoprotein particle receptor binding; low-density lipoprotein particle receptor binding; peptidase activity; serine-type endopeptidase activity; serine-type endop

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.